Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Dapagliflozin; Glipizide; Metformin

Criteria

Inclusion Criteria:

• Type 2 Diabetes

• Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment

• HbA1c >6.5% and Exclusion Criteria:

• Type 1 Diabetes

• Insulin therapy within one year of enrolment

• Renal (kidney) failure or dysfunction